X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (93) 93
humans (86) 86
oncology (85) 85
male (69) 69
cancer (44) 44
middle aged (42) 42
aged (36) 36
female (34) 34
metastasis (33) 33
carcinoma, renal cell - drug therapy (31) 31
kidney neoplasms - drug therapy (29) 29
kidney neoplasms - pathology (28) 28
adult (26) 26
care and treatment (26) 26
prostate cancer (26) 26
treatment outcome (25) 25
urology (24) 24
urology & nephrology (24) 24
aged, 80 and over (23) 23
antineoplastic agents - therapeutic use (22) 22
sunitinib (22) 22
carcinoma, renal cell (20) 20
survival (20) 20
interferon-alpha (19) 19
prognosis (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
carcinoma, renal cell - mortality (18) 18
disease-free survival (18) 18
hematology, oncology and palliative medicine (18) 18
renal cell carcinoma (18) 18
kidney neoplasms - mortality (17) 17
chemotherapy (16) 16
neoplasm metastasis (16) 16
carcinoma, renal cell - pathology (15) 15
immunotherapy (15) 15
sorafenib (15) 15
clinical trials (14) 14
efficacy (14) 14
everolimus (14) 14
prostatic neoplasms - drug therapy (14) 14
prostatic neoplasms - pathology (14) 14
kidney cancer (13) 13
docetaxel (12) 12
drug therapy (12) 12
retrospective studies (12) 12
safety (12) 12
analysis (11) 11
carcinoma, renal cell - secondary (11) 11
endothelial growth-factor (11) 11
patients (11) 11
research (11) 11
therapy (11) 11
abridged index medicus (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
antineoplastic agents - adverse effects (9) 9
bevacizumab (9) 9
carcinoma (9) 9
double-blind (9) 9
drug administration schedule (9) 9
neoplasm staging (9) 9
angiogenesis inhibitors (8) 8
antimitotic agents (8) 8
antineoplastic agents (8) 8
disease progression (8) 8
follow-up studies (8) 8
hematology (8) 8
italy (8) 8
metastases (8) 8
metastatic renal cell carcinoma (8) 8
patient outcomes (8) 8
phase-iii trial (8) 8
prostatic neoplasms - therapy (8) 8
protein kinase inhibitors - therapeutic use (8) 8
quality of life (8) 8
radical prostatectomy (8) 8
survival analysis (8) 8
targeted therapy (8) 8
trial (8) 8
tumors (8) 8
antineoplastic agents - administration & dosage (7) 7
cancer therapies (7) 7
clear cell-type renal cell carcinoma (7) 7
development and progression (7) 7
double-blind method (7) 7
guidelines (7) 7
kidney neoplasms - therapy (7) 7
prognostic factors (7) 7
survival rate (7) 7
taxoids - administration & dosage (7) 7
taxoids - therapeutic use (7) 7
vascular endothelial growth factor (7) 7
combined modality therapy (6) 6
drug resistance, neoplasm (6) 6
indoles - therapeutic use (6) 6
kaplan-meier estimate (6) 6
management (6) 6
medical colleges (6) 6
medical prognosis (6) 6
medicine, general & internal (6) 6
niacinamide - analogs & derivatives (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 312 - 322
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9605, pp. 2103 - 2111
Journal Article
European Urology, ISSN 0302-2838, 2012, Volume 63, Issue 2, pp. 264 - 265
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9637, pp. 449 - 456
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1599 - 1611
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
European Urology, ISSN 0302-2838, 10/2018, Volume 74, Issue 4, pp. 481 - 482
Journal Article
Journal of Urology, ISSN 0022-5347, 09/2017, Volume 198, Issue 3, pp. 536 - 537
Journal Article
The Journal of Urology, ISSN 0022-5347, 09/2017, Volume 198, Issue 3, pp. 536 - 537
Journal Article
Journal of Urology, ISSN 0022-5347, 09/2017, Volume 198, Issue 3, pp. 536 - 537
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2017
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma | Index Medicus
Journal Article